SKYE BIOSCIENCE INC (SKYE)
US83086J2006 - Common Stock
Taking everything into account, SKYE scores 3 out of 10 in our fundamental rating. SKYE was compared to 564 industry peers in the Biotechnology industry. While SKYE has a great health rating, there are worries on its profitability. SKYE has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
SKYE had negative earnings in the past year.
In the past year SKYE has reported a negative cash flow from operations.
In the past 5 years SKYE reported 4 times negative net income.
SKYE had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
SKYE's Return On Assets of -26.05% is fine compared to the rest of the industry. SKYE outperforms 72.53% of its industry peers.
SKYE has a Return On Equity of -28.02%. This is amongst the best in the industry. SKYE outperforms 80.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.05% | ||
| ROE | -28.02% | ||
| ROIC | N/A |
ROA(3y)-205.17%
ROA(5y)-161.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for SKYE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SKYE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SKYE has more shares outstanding
The debt/assets ratio for SKYE is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 6.92 indicates that SKYE is not in any danger for bankruptcy at the moment.
The Altman-Z score of SKYE (6.92) is better than 83.12% of its industry peers.
SKYE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.92 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
SKYE has a Current Ratio of 14.19. This indicates that SKYE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 14.19, SKYE belongs to the top of the industry, outperforming 88.69% of the companies in the same industry.
SKYE has a Quick Ratio of 14.19. This indicates that SKYE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 14.19, SKYE belongs to the top of the industry, outperforming 88.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 14.19 | ||
| Quick Ratio | 14.19 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 90.35% over the past year.
EPS 1Y (TTM)90.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
SKYE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.92% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y83.74%
EPS Next 2Y33.77%
EPS Next 3Y20.03%
EPS Next 5Y8.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
SKYE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SKYE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SKYE's earnings are expected to grow with 20.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.77%
EPS Next 3Y20.03%
5. Dividend
5.1 Amount
No dividends for SKYE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SKYE BIOSCIENCE INC
NASDAQ:SKYE (1/3/2025, 8:02:41 PM)
After market: 2.85 0 (0%)2.85
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners81.1%
Inst Owner Change7.89%
Ins Owners1.89%
Ins Owner Change-0.13%
Market Cap86.47M
Analysts83.33
Price Target18.36 (544.21%)
Short Float %5.91%
Short Ratio8.95
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)30.17%
Min EPS beat(2)-0.55%
Max EPS beat(2)60.89%
EPS beat(4)1
Avg EPS beat(4)-3.12%
Min EPS beat(4)-62.54%
Max EPS beat(4)60.89%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.27%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-24.35%
EPS NY rev (1m)2.73%
EPS NY rev (3m)14.88%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.14 | ||
| P/tB | 1.14 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.11
EYN/A
EPS(NY)-1.17
Fwd EYN/A
FCF(TTM)-0.74
FCFYN/A
OCF(TTM)-0.69
OCFYN/A
SpS0
BVpS2.5
TBVpS2.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.05% | ||
| ROE | -28.02% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-205.17%
ROA(5y)-161.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1054.57% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 14.19 | ||
| Quick Ratio | 14.19 | ||
| Altman-Z | 6.92 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)128.37%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.83%
EPS Next Y83.74%
EPS Next 2Y33.77%
EPS Next 3Y20.03%
EPS Next 5Y8.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y16.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-117.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-112.68%
OCF growth 3YN/A
OCF growth 5YN/A